Cytokine profiles of phakic and pseudophakic eyes with primary retinal detachment.
biomarkers
chemokines
cytokines
interleukins
macular hole
rhegmatogenous retinal detachment
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
24
09
2018
accepted:
16
11
2018
pubmed:
19
12
2018
medline:
14
5
2019
entrez:
19
12
2018
Statut:
ppublish
Résumé
To compare the cytokine profiles of phakic (p) and pseudophakic (ps) eyes with primary rhegmatogenous retinal detachment (RD) to eyes with macular holes (MH) and to identify differences in the specific cytokine profiles. Aqueous humour (AH) and vitreous fluid (VF) were obtained from patients with primary RD without proliferative vitreoretinopathy undergoing vitrectomy. AH and VF of patients with macular holes (MH) served as controls. Forty-three different cytokines were quantified using multiplex cytokine analysis. Intergroup and intragroup comparisons were performed. To control for multiple comparisons, Holm's correction was applied. VF and AH samples of 71 eyes with RD (pRD N = 38; psRD N = 33) and 26 eyes with MH were included. Cytokine levels in psRD and pRD were similar (none with >10-fold difference). The levels of 39 of 43 cytokines in the VF were significantly higher in eyes with RD than in those with MH (>10-fold: CXLC5, CCL26, CCL1, IL-6, CXCL11, CCL7, CCL13, MIG/CXCL9, CCL19 and TGF-β1). In the AH, 23 of 43 cytokines were significantly higher compared to MH (>10-fold: CXCL5, IL-4, IL-6, IL-8/CXCL8 and CCL7). A complex, but nonspecific cytokine environmental response seems to initiate immunological and profibrotic processes following RD. Relevant differences in the cytokine profiles of eyes with pRD and psRD were not identified, whereas cytokine differences between AH and VF in RD could be explained by upregulation in the vitreous, a higher turn around in the anterior chamber, or differences in inflammatory cascades in both compartments.
Identifiants
pubmed: 30561135
doi: 10.1111/aos.13998
pmc: PMC6590374
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e580-e588Subventions
Organisme : Scientific Funds of the Lindenhof Foundation.
Informations de copyright
© 2018 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.
Références
J Immunol. 1999 Aug 1;163(3):1602-10
pubmed: 10415065
Br J Ophthalmol. 2001 Apr;85(4):461-70
pubmed: 11264138
Prog Retin Eye Res. 2002 Jan;21(1):127-44
pubmed: 11906814
Invest Ophthalmol Vis Sci. 2003 Sep;44(9):4054-60
pubmed: 12939328
Am J Ophthalmol. 1992 Dec 15;114(6):731-6
pubmed: 1463043
Eur J Immunol. 2004 Oct;34(10):2885-94
pubmed: 15368305
J Cataract Refract Surg. 2005 Feb;31(2):354-8
pubmed: 15767158
Int J Med Microbiol. 2005 Aug;295(4):287-95
pubmed: 16128403
Compr Ophthalmol Update. 2006 Jul-Aug;7(4):179-85
pubmed: 17007731
Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2425-30
pubmed: 17284607
Invest Ophthalmol Vis Sci. 2007 May;48(5):2203-7
pubmed: 17460280
Exp Eye Res. 2007 Sep;85(3):366-80
pubmed: 17662275
Ophthalmic Surg Lasers Imaging. 2007 Sep-Oct;38(5):365-70
pubmed: 17955840
Mol Vis. 2007 Oct 29;13:2048-57
pubmed: 18079678
J Immunol. 2008 Mar 15;180(6):3789-96
pubmed: 18322185
Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1262-73
pubmed: 18326757
Invest Ophthalmol Vis Sci. 2008 Jul;49(7):3193-200
pubmed: 18378582
J Fr Ophtalmol. 2008 Jan;31(1):36-41
pubmed: 18401297
Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4620-30
pubmed: 18450597
Histol Histopathol. 2008 Nov;23(11):1399-407
pubmed: 18785122
Graefes Arch Clin Exp Ophthalmol. 2010 Jan;248(1):21-30
pubmed: 19779932
Exp Eye Res. 2010 Mar;90(3):376-81
pubmed: 19931527
PLoS One. 2009 Dec 04;4(12):e8158
pubmed: 19997642
Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4143-50
pubmed: 20335622
Curr Eye Res. 2010 Jun;35(6):505-9
pubmed: 20465445
Mol Vis. 2010 Sep 12;16:1864-73
pubmed: 21031020
Invest Ophthalmol Vis Sci. 2011 Mar 14;52(3):1384-91
pubmed: 21402953
Int Ophthalmol. 1990 Mar;14(2):105-17
pubmed: 2187005
Invest Ophthalmol Vis Sci. 2012 Dec 19;53(13):8472-80
pubmed: 23150618
Am J Pathol. 2013 May;182(5):1659-70
pubmed: 23582767
Surv Ophthalmol. 2013 Jul-Aug;58(4):321-9
pubmed: 23642514
Biochim Biophys Acta. 2014 Nov;1843(11):2563-2582
pubmed: 24892271
Mediators Inflamm. 2014;2014:396204
pubmed: 24994946
Clin Transl Med. 2015 Feb 07;4:2
pubmed: 25852818
Invest Ophthalmol Vis Sci. 2015 May;56(5):3407-14
pubmed: 26024125
Curr Mol Med. 2015;15(6):543-9
pubmed: 26238370
Rom J Ophthalmol. 2015 Apr-Jun;59(2):88-92
pubmed: 26978867
Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):6320-6326
pubmed: 27893098
BMC Ophthalmol. 2016 Dec 9;16(1):216
pubmed: 27938367
Int J Ophthalmol. 2016 Nov 18;9(11):1629-1633
pubmed: 27990367
Biomed Res Int. 2016;2016:4256183
pubmed: 28074184
Front Immunol. 2017 Feb 27;8:200
pubmed: 28289419
Retina. 2018 May 21;:null
pubmed: 29787465
Graefes Arch Clin Exp Ophthalmol. 1982;219(6):268-71
pubmed: 6761238
Invest Ophthalmol Vis Sci. 1994 Mar;35(3):900-6
pubmed: 8125753
Invest Ophthalmol Vis Sci. 1993 Nov;34(12):3376-85
pubmed: 8225872
Curr Eye Res. 1995 Nov;14(11):1045-53
pubmed: 8585935
Invest Ophthalmol Vis Sci. 1996 Oct;37(11):2318-25
pubmed: 8843916
Immunity. 1997 Mar;6(3):315-25
pubmed: 9075932